Compare LMT & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMT | VRTX |
|---|---|---|
| Founded | 1912 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | EDP Services |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.4B | 135.6B |
| IPO Year | 1995 | 2006 |
| Metric | LMT | VRTX |
|---|---|---|
| Price | $595.43 | $539.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 32 |
| Target Price | ★ $660.86 | $595.36 |
| AVG Volume (30 Days) | ★ 1.6M | 1.5M |
| Earning Date | 10-22-2026 | 11-02-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | N/A | ★ 836.54 |
| EPS | ★ 22.36 | 10.90 |
| Revenue | ★ $75,048,000,000.00 | $2,488,652,000.00 |
| Revenue This Year | $8.48 | $10.46 |
| Revenue Next Year | $7.03 | $10.53 |
| P/E Ratio | ★ $27.07 | $50.09 |
| Revenue Growth | 5.64 | ★ 46.20 |
| 52 Week Low | $437.25 | $412.27 |
| 52 Week High | $692.00 | $568.67 |
| Indicator | LMT | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.93 | 53.31 |
| Support Level | $593.88 | $493.75 |
| Resistance Level | $603.26 | $561.54 |
| Average True Range (ATR) | 17.85 | 16.77 |
| MACD | -3.96 | 0.07 |
| Stochastic Oscillator | 34.07 | 51.53 |
Lockheed Martin is the world's largest defense contractor and has dominated the Western market for high-end fighter aircraft since it won the F-35 Joint Strike Fighter program in 2001. Aeronautics is Lockheed's largest segment, which derives upward of two-thirds of its revenue from the F-35. Lockheed's remaining segments are rotary and mission systems, encompassing the Sikorsky helicopter business; missiles and fire control, which creates missiles and missile defense systems; and space systems, which produces satellites and receives equity income from the United Launch Alliance joint venture.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).